Live Earnings Conference Call: Spectral AI will host a live Q1 2026 earnings call on May 12, 2026 at 5:00PM ET. Get details.

Spectral AI (MDAI) Competitors

$2.19 -0.14 (-5.79%)

As of 02:49 PM Eastern

Compare

MDAI vs. TLSI, SI, PROF, CARL, and OBIO

Should you buy Spectral AI stock or one of its competitors? MarketBeat compares Spectral AI with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Spectral AI include TriSalus Life Sciences (TLSI), Shoulder Innovations (SI), Profound Medical (PROF), Carlsmed (CARL), and Orchestra BioMed (OBIO). These companies are all part of the "medical equipment" industry.

How does Spectral AI compare to TriSalus Life Sciences?

TriSalus Life Sciences (NASDAQ:TLSI) and Spectral AI (NASDAQ:MDAI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

In the previous week, TriSalus Life Sciences had 2 more articles in the media than Spectral AI. MarketBeat recorded 5 mentions for TriSalus Life Sciences and 3 mentions for Spectral AI. Spectral AI's average media sentiment score of 0.47 beat TriSalus Life Sciences' score of 0.22 indicating that Spectral AI is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TriSalus Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spectral AI	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spectral AI has a net margin of -41.11% compared to TriSalus Life Sciences' net margin of -86.88%.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-86.88%	N/A	-94.43%
Spectral AI	-41.11%	N/A	-35.64%

TriSalus Life Sciences has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, Spectral AI has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 67.1% of Spectral AI shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by company insiders. Comparatively, 30.7% of Spectral AI shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Spectral AI has lower revenue, but higher earnings than TriSalus Life Sciences. Spectral AI is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$45.15M	6.28	-$39.23M	-$1.83	N/A
Spectral AI	$19.65M	3.55	-$7.57M	-$0.31	N/A

TriSalus Life Sciences presently has a consensus target price of $7.00, suggesting a potential upside of 51.25%. Spectral AI has a consensus target price of $3.00, suggesting a potential upside of 36.67%. Given TriSalus Life Sciences' higher probable upside, equities research analysts clearly believe TriSalus Life Sciences is more favorable than Spectral AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Spectral AI beats TriSalus Life Sciences on 8 of the 13 factors compared between the two stocks.

How does Spectral AI compare to Shoulder Innovations?

Spectral AI (NASDAQ:MDAI) and Shoulder Innovations (NYSE:SI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

Spectral AI has higher earnings, but lower revenue than Shoulder Innovations. Spectral AI is trading at a lower price-to-earnings ratio than Shoulder Innovations, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectral AI	$19.65M	3.55	-$7.57M	-$0.31	N/A
Shoulder Innovations	$47.32M	5.80	-$40.36M	-$218.68	N/A

In the previous week, Spectral AI had 2 more articles in the media than Shoulder Innovations. MarketBeat recorded 3 mentions for Spectral AI and 1 mentions for Shoulder Innovations. Spectral AI's average media sentiment score of 0.47 beat Shoulder Innovations' score of 0.00 indicating that Spectral AI is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spectral AI	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Shoulder Innovations	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spectral AI has a net margin of -41.11% compared to Shoulder Innovations' net margin of -85.29%. Spectral AI's return on equity of 0.00% beat Shoulder Innovations' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spectral AI	-41.11%	N/A	-35.64%
Shoulder Innovations	-85.29%	-37.68%	-18.63%

Spectral AI currently has a consensus price target of $3.00, indicating a potential upside of 36.67%. Shoulder Innovations has a consensus price target of $21.00, indicating a potential upside of 58.73%. Given Shoulder Innovations' stronger consensus rating and higher possible upside, analysts plainly believe Shoulder Innovations is more favorable than Spectral AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Shoulder Innovations	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

67.1% of Spectral AI shares are held by institutional investors. 30.7% of Spectral AI shares are held by company insiders. Comparatively, 29.0% of Shoulder Innovations shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Spectral AI beats Shoulder Innovations on 8 of the 15 factors compared between the two stocks.

How does Spectral AI compare to Profound Medical?

Spectral AI (NASDAQ:MDAI) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Spectral AI has higher revenue and earnings than Profound Medical. Spectral AI is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectral AI	$19.65M	3.55	-$7.57M	-$0.31	N/A
Profound Medical	$16.10M	16.26	-$42.57M	-$1.24	N/A

In the previous week, Profound Medical had 4 more articles in the media than Spectral AI. MarketBeat recorded 7 mentions for Profound Medical and 3 mentions for Spectral AI. Profound Medical's average media sentiment score of 0.62 beat Spectral AI's score of 0.47 indicating that Profound Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spectral AI	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Profound Medical	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Spectral AI has a net margin of -41.11% compared to Profound Medical's net margin of -206.76%. Spectral AI's return on equity of 0.00% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spectral AI	-41.11%	N/A	-35.64%
Profound Medical	-206.76%	-78.88%	-64.06%

Spectral AI currently has a consensus price target of $3.00, indicating a potential upside of 36.67%. Profound Medical has a consensus price target of $12.00, indicating a potential upside of 66.55%. Given Profound Medical's higher probable upside, analysts plainly believe Profound Medical is more favorable than Spectral AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

67.1% of Spectral AI shares are owned by institutional investors. Comparatively, 47.9% of Profound Medical shares are owned by institutional investors. 30.7% of Spectral AI shares are owned by insiders. Comparatively, 1.5% of Profound Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Spectral AI has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market.

Summary

Spectral AI beats Profound Medical on 9 of the 14 factors compared between the two stocks.

How does Spectral AI compare to Carlsmed?

Spectral AI (NASDAQ:MDAI) and Carlsmed (NASDAQ:CARL) are both small-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Spectral AI currently has a consensus price target of $3.00, indicating a potential upside of 36.67%. Carlsmed has a consensus price target of $19.33, indicating a potential upside of 95.78%. Given Carlsmed's stronger consensus rating and higher possible upside, analysts clearly believe Carlsmed is more favorable than Spectral AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

67.1% of Spectral AI shares are owned by institutional investors. 30.7% of Spectral AI shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Spectral AI has higher earnings, but lower revenue than Carlsmed. Spectral AI is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectral AI	$19.65M	3.55	-$7.57M	-$0.31	N/A
Carlsmed	$50.51M	5.31	-$29.63M	-$2.51	N/A

In the previous week, Carlsmed had 6 more articles in the media than Spectral AI. MarketBeat recorded 9 mentions for Carlsmed and 3 mentions for Spectral AI. Carlsmed's average media sentiment score of 0.61 beat Spectral AI's score of 0.47 indicating that Carlsmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spectral AI	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Carlsmed	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spectral AI has a net margin of -41.11% compared to Carlsmed's net margin of -57.76%. Spectral AI's return on equity of 0.00% beat Carlsmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spectral AI	-41.11%	N/A	-35.64%
Carlsmed	-57.76%	-60.74%	-29.84%

Summary

Carlsmed beats Spectral AI on 9 of the 15 factors compared between the two stocks.

How does Spectral AI compare to Orchestra BioMed?

Orchestra BioMed (NASDAQ:OBIO) and Spectral AI (NASDAQ:MDAI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

Orchestra BioMed currently has a consensus price target of $14.25, indicating a potential upside of 258.04%. Spectral AI has a consensus price target of $3.00, indicating a potential upside of 36.67%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, equities research analysts clearly believe Orchestra BioMed is more favorable than Spectral AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

53.2% of Orchestra BioMed shares are owned by institutional investors. Comparatively, 67.1% of Spectral AI shares are owned by institutional investors. 8.1% of Orchestra BioMed shares are owned by company insiders. Comparatively, 30.7% of Spectral AI shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Spectral AI has lower revenue, but higher earnings than Orchestra BioMed. Spectral AI is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$33.48M	7.12	-$52.70M	-$1.13	N/A
Spectral AI	$19.65M	3.55	-$7.57M	-$0.31	N/A

Orchestra BioMed has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, Spectral AI has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market.

In the previous week, Orchestra BioMed had 3 more articles in the media than Spectral AI. MarketBeat recorded 6 mentions for Orchestra BioMed and 3 mentions for Spectral AI. Orchestra BioMed's average media sentiment score of 0.48 beat Spectral AI's score of 0.47 indicating that Orchestra BioMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orchestra BioMed	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spectral AI	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spectral AI has a net margin of -41.11% compared to Orchestra BioMed's net margin of -157.40%. Spectral AI's return on equity of 0.00% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-157.40%	-184.17%	-65.56%
Spectral AI	-41.11%	N/A	-35.64%

Summary

Orchestra BioMed and Spectral AI tied by winning 8 of the 16 factors compared between the two stocks.

Get Spectral AI News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDAI vs. The Competition

Export

Metric	Spectral AI	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$69.85M	$6.84B	$6.28B	$12.10B
Dividend Yield	N/A	1.72%	2.78%	5.23%
P/E Ratio	-7.08	49.38	20.55	25.41
Price / Sales	3.55	63.63	545.88	75.53
Price / Cash	N/A	25.20	27.81	36.29
Price / Book	-11.55	6.63	9.62	6.65
Net Income	-$7.57M	$158.34M	$3.55B	$333.40M
7 Day Performance	-3.30%	1.16%	-0.36%	-0.58%
1 Month Performance	26.88%	6.89%	5.99%	7.66%
1 Year Performance	61.40%	-2.99%	38.59%	35.36%

Spectral AI Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDAI Spectral AI	2.0297 of 5 stars	$2.20 -5.8%	$3.00 +36.7%	+87.9%	$69.85M	$19.65M	N/A	83
TLSI TriSalus Life Sciences	2.1256 of 5 stars	$4.61 +3.6%	$7.00 +51.8%	-9.6%	$282.64M	$45.15M	N/A	106
SI Shoulder Innovations	3.174 of 5 stars	$12.95 -0.6%	$20.80 +60.6%	N/A	$268.41M	$47.32M	N/A	61
PROF Profound Medical	1.561 of 5 stars	$7.27 +8.5%	$12.00 +65.1%	+56.6%	$264.18M	$16.10M	N/A	150	Earnings Report
CARL Carlsmed	3.0208 of 5 stars	$8.92 -1.9%	$19.67 +120.5%	N/A	$242.89M	$50.51M	N/A	100	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDAI) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spectral AI (MDAI) Competitors

MDAI vs. TLSI, SI, PROF, CARL, and OBIO

How does Spectral AI compare to TriSalus Life Sciences?

Summary

How does Spectral AI compare to Shoulder Innovations?

Summary

How does Spectral AI compare to Profound Medical?

Summary

How does Spectral AI compare to Carlsmed?

Summary

How does Spectral AI compare to Orchestra BioMed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDAI vs. The Competition

Spectral AI Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spectral AI (MDAI) Competitors

MDAI vs. TLSI, SI, PROF, CARL, and OBIO

How does Spectral AI compare to TriSalus Life Sciences?

Does the media refer more to TLSI or MDAI?

Is TLSI or MDAI more profitable?

Which has more risk & volatility, TLSI or MDAI?

Do institutionals and insiders hold more shares of TLSI or MDAI?

Which has preferable earnings & valuation, TLSI or MDAI?

Do analysts recommend TLSI or MDAI?

Summary

How does Spectral AI compare to Shoulder Innovations?

Which has stronger valuation & earnings, MDAI or SI?

Does the media favor MDAI or SI?

Is MDAI or SI more profitable?

Do analysts recommend MDAI or SI?

Do institutionals & insiders believe in MDAI or SI?

Summary

How does Spectral AI compare to Profound Medical?

Which has higher valuation and earnings, MDAI or PROF?

Does the media prefer MDAI or PROF?

Is MDAI or PROF more profitable?

Do analysts prefer MDAI or PROF?

Do institutionals & insiders believe in MDAI or PROF?

Which has more volatility & risk, MDAI or PROF?

Summary

How does Spectral AI compare to Carlsmed?

Do analysts prefer MDAI or CARL?

Do insiders and institutionals believe in MDAI or CARL?

Which has stronger valuation & earnings, MDAI or CARL?

Does the media refer more to MDAI or CARL?

Is MDAI or CARL more profitable?

Summary

How does Spectral AI compare to Orchestra BioMed?

Do analysts prefer OBIO or MDAI?

Do institutionals and insiders believe in OBIO or MDAI?

Which has higher valuation and earnings, OBIO or MDAI?

Which has more risk and volatility, OBIO or MDAI?

Does the media favor OBIO or MDAI?

Is OBIO or MDAI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDAI vs. The Competition

Spectral AI Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools